MYWOT

Child safety

N/A

Confidence

0%

Trustworthiness

N/A

Confidence

0%

MALICIOUS CONTENT INDICATORS

Availability or unavailability of the flaggable/dangerous content on this website has not been fully explored by us, so you should rely on the following indicators with caution.

Stemedica.com most likely does not offer any malicious content.

  • Siteadvisor

    Safety status

    N/A

  • SAFEBROWSING

    Safety status

    Safe

  • Phishtank

    Safety status

    N/A

Secure connection support

HTTPS

Stemedica.com provides SSL-encrypted connection.

ADULT CONTENT INDICATORS

Availability or unavailability of the flaggable/dangerous content on this website has not been fully explored by us, so you should rely on the following indicators with caution.

Stemedica.com most likely does not offer any adult content.

Popular pages

  • About Us | Stemedica

    Company Overview Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for unders...

  • Clinical | Stemedica

    Strategy Stemedica conducts extensive pre-clinical and clinical research with partners to generate empirical data on the translational value of progenitor cell-based therapies for medical conditions a...

  • Stemedica Initiating Phase IIb/III Clinical Trial for Patients with Chronic Ischemic Stroke

    SAN DIEGO, California – January 19, 2023. Stemedica Cell Technologies, a best-in-class manufacturer of ischemic tolerant, allogeneic mesenchymal stem cells (itMSC), announced today that it has initia...

  • Technology | Stemedica

    Stemedica has developed and executed a proprietary platform — BioSmart Technology™— for manufacturing non-embryonic allogeneic progenitor cells. This platform provides a competitive advantage in its a...

  • Stemedica Opens Enrollment in Phase II Clinical Trial for COVID-19 A Phase II Study in Patients with

    Select Page Stemedica Opens Enrollment in Phase II Clinical Trial for COVID-19 A Phase II Study in Patients with Moderate to Severe ARDS Using GMP, Allogeneic, Bone Marrow-Derived, Ischemic...

  • Clinical Trials | Stemedica

    by stemedica admin | Sep 27, 2020 | Clinical TrialsSAN DIEGO, Calif. — September 28, 2020 — Stemedica Cell Technologies, Inc. has received U.S. Food and Drug Administration (FDA) Investigational New D...

Open neighbouring websites list